<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03916744</url>
  </required_header>
  <id_info>
    <org_study_id>GO40987</org_study_id>
    <secondary_id>2018-003798-85</secondary_id>
    <nct_id>NCT03916744</nct_id>
  </id_info>
  <brief_title>A Study of Giredestrant (GDC-9545) in Postmenopausal Women With Stage I-III Operable, Estrogen Receptor-Positive Breast Cancer</brief_title>
  <official_title>A Phase I, Multicenter, Open-Label Preoperative, Short-Term Window Study of GDC-9545 in Postmenopausal Women With Stage I-III Operable, Estrogen Receptor-Positive Breast Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Genentech, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Genentech, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will evaluate the pharmacodynamics, pharmacokinetics, safety, and biologic&#xD;
      activity of giredestrant in participants with Stage I-III operable estrogen receptor&#xD;
      (ER)-positive, human epidermal growth factor receptor 2 (HER2)-negative, untreated breast&#xD;
      cancer.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">July 26, 2019</start_date>
  <completion_date type="Actual">May 25, 2021</completion_date>
  <primary_completion_date type="Actual">May 25, 2021</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change from Baseline in Tumor Cell Proliferation Measured by Ki67 Expression Between Pre- and Post-Treatment Tumor Biopsy Samples</measure>
    <time_frame>Baseline and Day 14 or Day 15</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Participants with at Least One Adverse Event and by Severity, Determined According to National Cancer Institute Common Terminology Criteria for Adverse Events, Version 5.0 (NCI-CTCAE v5.0)</measure>
    <time_frame>From Baseline to Day 43</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in Pulse Rate</measure>
    <time_frame>Baseline, Days 1, 8, 15, and 43</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in Systolic Blood Pressure</measure>
    <time_frame>Baseline, Days 1, 8, 15, and 43</time_frame>
    <description>Systolic blood pressure will be measured while the participant is in a seated position.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in Diastolic Blood Pressure</measure>
    <time_frame>Baseline, Days 1, 8, 15, and 43</time_frame>
    <description>Diastolic blood pressure will be measured while the participant is in a seated position.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in Body Temperature</measure>
    <time_frame>Baseline, Days 1, 8, 15, and 43</time_frame>
    <description>Body temperature will be taken by oral or tympanic temperature.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in Prothrombin Time (PT)</measure>
    <time_frame>Baseline, Days 1, 8, 15, and 43</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in Activated Partial Thromboplastin Time (aPTT)</measure>
    <time_frame>Baseline, Days 1, 8, 15, and 43</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in International Normalized Ratio (INR)</measure>
    <time_frame>Baseline, Days 1, 8, 15, and 43</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants with Laboratory Abnormalities in Hematology Tests by Highest Grade According to NCI-CTCAE v5.0</measure>
    <time_frame>Baseline, Days 1, 8, and 15</time_frame>
    <description>Laboratory parameters for hematology will be measured and compared with a standard reference range. Values outside of the standard reference range are considered abnormalities. Not every laboratory abnormality qualifies as an adverse event. A laboratory test result will be reported as an adverse event if it meets any of the following criteria: is accompanied by clinical symptoms; results in a change in study treatment, a medical intervention, or a change in concomitant therapy; or is clinically significant in the investigator's judgment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants with Laboratory Abnormalities in Blood Chemistry Tests by Highest Grade According to NCI-CTCAE v5.0</measure>
    <time_frame>Baseline, Days 1, 8, and 15</time_frame>
    <description>Laboratory parameters for blood chemistry will be measured and compared with a standard reference range. Values outside of the standard reference range are considered abnormalities. Not every laboratory abnormality qualifies as an adverse event. A laboratory test result will be reported as an adverse event if it meets any of the following criteria: is accompanied by clinical symptoms; results in a change in study treatment, a medical intervention, or a change in concomitant therapy; or is clinically significant in the investigator's judgment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma Concentration of Giredestrant at Steady State</measure>
    <time_frame>Day 15</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">75</enrollment>
  <condition>Breast Cancer</condition>
  <arm_group>
    <arm_group_label>Giredestrant Dose Level 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Giredestrant Dose Level 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Giredestrant Dose Level 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Giredestrant</intervention_name>
    <description>Giredestrant will be administered orally once daily (QD) starting on Day 1 up to and including the day of surgery (if allowed per local process) on Day 15 (+/-2 days).</description>
    <arm_group_label>Giredestrant Dose Level 1</arm_group_label>
    <arm_group_label>Giredestrant Dose Level 2</arm_group_label>
    <arm_group_label>Giredestrant Dose Level 3</arm_group_label>
    <other_name>GDC-9545</other_name>
    <other_name>RO7197597</other_name>
    <other_name>RG6171</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Surgery</intervention_name>
    <description>Breast cancer surgery will take place on Day 15 (+/-2 days).</description>
    <arm_group_label>Giredestrant Dose Level 1</arm_group_label>
    <arm_group_label>Giredestrant Dose Level 2</arm_group_label>
    <arm_group_label>Giredestrant Dose Level 3</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Ability to comply with the study protocol, in the investigator's judgment&#xD;
&#xD;
          -  Histologically confirmed invasive breast carcinoma, with all of the following&#xD;
             characteristics: Primary tumor greater than or equal to (≥)1.5 centimeters (cm) in&#xD;
             largest diameter by ultrasound; Stage I-III operable breast cancer; Documentation&#xD;
             confirming the absence of distant metastasis (M0) as determined by institutional&#xD;
             practice.&#xD;
&#xD;
          -  ER-positive tumor and HER2-negative breast cancer as per local laboratory testing&#xD;
&#xD;
          -  Postmenopausal status&#xD;
&#xD;
          -  Breast cancer eligible for primary surgery&#xD;
&#xD;
          -  Submission of a representative tumor tissue specimen&#xD;
&#xD;
          -  Eastern Cooperative Oncology Group (ECOG) Performance Status less than or equal to&#xD;
             (≤)1&#xD;
&#xD;
          -  Adequate organ function&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Diagnosis of inflammatory breast cancer&#xD;
&#xD;
          -  Diagnosis of bilateral breast cancer&#xD;
&#xD;
          -  Concurrent use of hormone replacement therapies&#xD;
&#xD;
          -  Previous systemic or local treatment for the primary breast cancer currently under&#xD;
             investigation&#xD;
&#xD;
          -  Concurrent treatment with other experimental drugs or participation in another&#xD;
             clinical trial with any investigational drug within 30 days prior to study entry&#xD;
&#xD;
          -  Current treatment with any systemic anti-cancer therapies&#xD;
&#xD;
          -  Major surgery within 4 weeks prior to enrollment&#xD;
&#xD;
          -  Radiation therapy within 2 weeks prior to enrollment&#xD;
&#xD;
          -  Diagnosis of any secondary malignancy within 3 years prior to enrollment, except for&#xD;
             appropriately treated carcinoma in situ of the cervix, non-melanoma skin carcinoma, or&#xD;
             Stage I uterine cancer&#xD;
&#xD;
          -  Active inflammatory bowel disease or chronic diarrhea, short bowel syndrome, or upper&#xD;
             gastrointestinal surgery including gastric resection&#xD;
&#xD;
          -  Known HIV infection&#xD;
&#xD;
          -  Known clinically significant history of liver disease consistent with Child-Pugh Class&#xD;
             B or C, including active viral or other hepatitis, current alcohol abuse, or cirrhosis&#xD;
&#xD;
          -  Other severe acute or chronic medical or psychiatric condition or laboratory&#xD;
             abnormality that may increase the risk associated with study participation or&#xD;
             investigational product administration or may interfere with the interpretation of&#xD;
             study results and, in the judgment of the investigator, would make the patient&#xD;
             inappropriate for entry into this study&#xD;
&#xD;
          -  History of allergy to giredestrant or any of its excipients&#xD;
&#xD;
          -  Any condition requiring anti-coagulants, such as warfarin, heparin, or thrombolytic&#xD;
             drugs&#xD;
&#xD;
          -  History of documented hemorrhagic diathesis or coagulopathy&#xD;
&#xD;
          -  History or presence of symptomatic bradycardia or sick sinus syndrome&#xD;
&#xD;
          -  Baseline heart rate ≤55 beats per minute (bpm) prior to enrollment&#xD;
&#xD;
          -  History or presence of an abnormal electrocardiogram (ECG) that is clinically&#xD;
             significant in the investigator's opinion, including complete left bundle branch&#xD;
             block, second- or third-degree heart block, or evidence of prior myocardial infarction&#xD;
&#xD;
          -  QT interval corrected through use of Fridericia's formula (QTcF) &gt;470 milliseconds&#xD;
             demonstrated by at least two ECGs &gt;30 minutes apart&#xD;
&#xD;
          -  History of ventricular dysrhythmias or risk factors for ventricular dysrhythmias such&#xD;
             as structural heart disease, coronary heart disease, clinically significant&#xD;
             electrolyte abnormalities, or family history of sudden unexplained death or long QT&#xD;
             syndrome&#xD;
&#xD;
          -  Current treatment with medications that are well known to prolong the QT interval&#xD;
&#xD;
          -  History or presence of uncontrolled hypothyroidism&#xD;
&#xD;
          -  Any other disease, metabolic dysfunction, physical examination finding, or clinical&#xD;
             laboratory finding that, in the investigator's opinion, gives reasonable suspicion of&#xD;
             a disease or condition that contraindicates the use of an investigational drug or that&#xD;
             may affect the interpretation of the results or render the patient at high risk from&#xD;
             treatment complications&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Clinical Trials</last_name>
    <role>Study Director</role>
    <affiliation>Hoffmann-La Roche</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Colorado</name>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <zip>80045-2517</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Colorado Health Lone Tree Medical Center</name>
      <address>
        <city>Lone Tree</city>
        <state>Colorado</state>
        <zip>80124</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Massachusetts General Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Memorial Sloan Kettering Cancer Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10065</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St Vincent's Hospital Sydney</name>
      <address>
        <city>Darlinghurst</city>
        <state>New South Wales</state>
        <zip>2010</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sunshine Hospital</name>
      <address>
        <city>St Albans</city>
        <state>Victoria</state>
        <zip>3021</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fiona Stanley Hospital; Investigational Drugs, Pharmacy Department</name>
      <address>
        <city>Murdoch</city>
        <state>Western Australia</state>
        <zip>6150</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinique Edith Cavell; Pharmacie</name>
      <address>
        <city>Auderghem</city>
        <zip>1160</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UZ Antwerpen</name>
      <address>
        <city>Edegem</city>
        <zip>2650</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Jessa Ziekenhuis</name>
      <address>
        <city>Hasselt</city>
        <zip>3500</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinique Sainte-Elisabeth; Oncologie</name>
      <address>
        <city>Namur</city>
        <zip>5000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GasthuisZusters Antwerpen</name>
      <address>
        <city>Wilrijk</city>
        <zip>2610</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Oscar Lambret</name>
      <address>
        <city>Lille</city>
        <zip>59020</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Eugene Marquis Centre Regional de Lutte Contre Le Cancer</name>
      <address>
        <city>Rennes</city>
        <zip>35000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Rene Gauducheau</name>
      <address>
        <city>Saint Herblain</city>
        <zip>44805</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>HOPITAL RENE HUGUENIN- Institut Curie</name>
      <address>
        <city>Saint-Cloud</city>
        <zip>92211</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institut Claudius Régaud</name>
      <address>
        <city>Toulouse</city>
        <zip>31059</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Onkologikoa - Instituto Oncológico de Donostia</name>
      <address>
        <city>San Sebastian</city>
        <state>Guipuzcoa</state>
        <zip>20014</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitari Vall d'Hebron</name>
      <address>
        <city>Barcelona</city>
        <zip>08035</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Ruber Internacional;Servicio de Oncologia</name>
      <address>
        <city>Madrid</city>
        <zip>28034</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>HM Sanchinarro - CIOCC</name>
      <address>
        <city>Madrid</city>
        <zip>28050</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Clinico Universitario de Valencia</name>
      <address>
        <city>Valencia</city>
        <zip>46010</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clatterbridge Cancer Centre Liverpool</name>
      <address>
        <city>Liverpool</city>
        <zip>L7 8XP</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Barts Health NHS Trust; William Harvey Heart Centre, QMUL School of Medicine &amp; Dentistry</name>
      <address>
        <city>London</city>
        <zip>EC1M 6BQ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Royal Cornwall Hospital</name>
      <address>
        <city>Truro</city>
        <zip>TR1 3LQ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>Belgium</country>
    <country>France</country>
    <country>Spain</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <removed_countries>
    <country>Germany</country>
  </removed_countries>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>April 10, 2019</study_first_submitted>
  <study_first_submitted_qc>April 12, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">April 16, 2019</study_first_posted>
  <last_update_submitted>June 15, 2021</last_update_submitted>
  <last_update_submitted_qc>June 15, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 18, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>Qualified researchers may request access to individual patient level data through the request platform (www.vivli.org). Further details on Roche's criteria for eligible studies are available here (https://vivli.org/ourmember/roche/).&#xD;
For further details on Roche's Global Policy on Sharing of Clinical Study Information and how to request access to related clinical study documents, see here (https://www.roche.com/research_and_development/who_we_are_how_we_work/clinical_trials/our_commitment_to_data_sharing.htm).</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

